Legal Representation
Attorney
DONNA J. BUNTON
USPTO Deadlines
Next Deadline
1624 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20240723)
Due Date
July 23, 2030
Grace Period Ends
January 23, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
45 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jul 23, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Jul 23, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jun 20, 2024 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Jun 20, 2024 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Jun 18, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jun 18, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jun 18, 2024 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Feb 9, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Feb 9, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Nov 9, 2023 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| Nov 9, 2023 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Aug 9, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Aug 9, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Aug 9, 2023 | CNRT | W | SU - NON-FINAL ACTION - WRITTEN | Loading... |
| Jul 19, 2023 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Jun 23, 2023 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Jul 19, 2023 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Jun 23, 2023 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Mar 2, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Feb 28, 2023 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Feb 28, 2023 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Feb 28, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Sep 2, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Aug 31, 2022 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Aug 31, 2022 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Aug 31, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 2, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Feb 28, 2022 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Feb 28, 2022 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Feb 28, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 31, 2021 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jul 20, 2021 | TMBN | T | TTAB RELEASE CASE TO TRADEMARKS | Loading... |
| Jul 20, 2021 | OP.T | T | OPPOSITION TERMINATED NO. 999999 | Loading... |
| Jul 20, 2021 | OP.D | T | OPPOSITION DISMISSED NO. 999999 | Loading... |
| Jul 23, 2020 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jun 29, 2020 | OP.I | T | OPPOSITION INSTITUTED NO. 999999 | Loading... |
| Jan 9, 2020 | ETOF | T | EXTENSION OF TIME TO OPPOSE RECEIVED | Loading... |
| Dec 31, 2019 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Dec 31, 2019 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Dec 11, 2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Nov 25, 2019 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Nov 22, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 9, 2019 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| Sep 6, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Aug 26, 2019 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Intravenous solution for use in the treatment of viral infections, immune disorders, cancer and ME/CFS; intravenous solution for use in the treatment of viral infections, immune disorders, cancer and ME/CFS; intravenous solution for use in the treatment of injuries resulting from surgery, thermal accidents or burns; Interferons; Parenterally administered interferon for use in treating viral diseases, immunological disorders and cancer; Pharmaceutical products, namely, pharmaceutical preparations for treatment of viral and infectious diseases, cancer, immune disorders and ME/CFS; intranasal solutions for use as a vaccine adjuvant, all of the foregoing primarily available by prescription
First Use Anywhere:
Jun 7, 2023
First Use in Commerce:
Jun 7, 2023
Class 042
Pharmaceutical research and development; Pharmaceutical research and development of drugs for the treatment of cancers, viral diseases, immunological disorders and ME/CFS
First Use Anywhere:
20190900
First Use in Commerce:
20190900
Additional Information
Pseudo Mark
AIM IMMUNOLOGICAL TECH
Classification
International Classes
005
042